secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001193125-23-171784
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA acquires LadRx royalty/milestone rights for arimoclomol and aldoxorubicin for $5M upfront
--------------------------------------------------------------------------------

- Acquired 100% of LadRx's royalty and milestone rights for arimoclomol (NPC) and aldoxorubicin (ImmunityBio).
- Paid $5M upfront; additional milestone payments of up to $6M may be required.
- Arimoclomol rights: $52.6M net milestones and mid-single-digit royalty from Zevra.
- Aldoxorubicin rights: mid-single-digit to mid-teens royalties and up to $343M milestones from ImmunityBio.
- Agreements include customary covenants, representations, and indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523171784/0001193125-23-171784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523171784/d468159d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-171784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer